tradipitant Report issue

Small molecule Experimental
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
Tradipitant is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. Vanda Pharmaceuticals is a U.S. pharmaceutical company that as of November 2015 only has three drugs in their product pipeline: tasimelteon, VLY-686, and iloperidone.   Wikipedia

Chemistry

  • SMILES: FC(F)(F)c1cc(Cn2nnc(c3ncccc3C(=O)c4ccccc4Cl)c2c5ccncc5)cc(c1)C(F)(F)F
  • InChIKey: CAVRKWRKTNINFF-UHFFFAOYSA-N
  • Mol. Mass: 587.91
  • ALogP: 7.37
  • ChEMBL Molecule:
    tradipitant  
More Chemistry

Pharmacology

Alternative names

ly686017 | ly-686017 | tradipitant | vly-686

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Alcoholism (Phase 2)

Coronavirus Infections (Phase 3)

Dermatitis, Atopic (Phase 3)

Diabetes Mellitus (Phase 3)

Dyspepsia (Phase 2)

Eczema (Phase 2)

Gastroparesis (Phase 3)

Healthy Volunteers (Phase 1)

Motion Sickness (Phase 3)

Phobia, Social (Phase 2)

Pruritus (Phase 2)

Stomach Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue